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Revisiting the human cholinergic nucleus of the diagonal band of Broca
Although the nucleus of the vertical limb of the diagonal
band of Broca (nvlDBB) is the second largest cholinergic
nucleus in the basal forebrain, after the nucleus basalis
of Meynert, it has not generally been a focus for studies
of neurodegenerative disorders. However, the nvlDBB
has an important projection to the hippocampus and dis-
crete lesions of the rostral basal forebrain have been
shown to disrupt retrieval memory function, a major def-
icit seen in patients with Lewy body disorders. One rea-
son for its neglect is that the anatomical boundaries of
the nvlDBB are ill defined and this area of the brain is
not part of routine diagnostic sampling protocols. We
have reviewed the history and anatomy of the nvlDBB
and now propose guidelines for distinguishing nvlDBB
from other neighbouring cholinergic cell groups for stan-
dardizing future clinicopathological work. Thorough
review of the literature regarding neurodegenerative
conditions reveals inconsistent results in terms of cholin-
ergic neuronal loss within the nvlDBB. This is likely to be
due to the use of variable neuronal inclusion criteria and
omission of cholinergic immunohistochemical markers.
Extrapolating from those studies showing a significant
nvlDBB neuronal loss in Lewy body dementia, we pro-
pose an anatomical and functional connection between
the cholinergic component of the nvlDBB (Ch2) and the
CA2 subfield in the hippocampus which may be espe-
cially vulnerable in Lewy body disorders.
Keywords: Alzheimer’s disease, basal forebrain, cholinergic system, diagonal band of Broca, Lewy body dementia,
Parkinson’s disease
Introduction
Brain cholinergic neurotransmitter systems are instru-
mental in many behavioural and cognitive processes
including attention, learning, memory, arousal and
sleep [1,2]. As suggested in the ‘Cholinergic
hypothesis’, a decreased level of acetylcholine in the
cerebral cortex and hippocampus has been shown to
contribute to the cognitive decline seen in ageing and
Alzheimer’s disease (AD) [3]. The cholinergic innerva-
tion of the neocortex and allocortex originates from the
cholinergic basal forebrain complex. In humans, this
complex is composed of interdigitating cell groups with
approximately 200 000 neurons per hemisphere [4–6].
Using acetylcholinesterase (AChE) histochemistry and
choline acetyltransferase (ChAT) immunohistochem-
istry, Mesulam and colleagues introduced ‘Ch’ sectoral
terminology to distinguish four groups of ChAT-
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immunopositive neurons within the basal forebrain
based on morphology and rostral–caudal organization
[7,8]. Ch1–Ch4 correspond to the cholinergic neurons
found in the medial septal nucleus (MSN), the nucleus of
the vertical limb of the diagonal band of Broca (nvlDBB),
the nucleus of the horizontal limb of the DBB (nhlDBB)
and the nucleus basalis of Meynert (nbM), respectively.
Retrograde tracer experiments using horseradish peroxi-
dase in nonhuman primates showed that Ch1 and Ch2
provide cholinergic efferents to the hippocampal com-
plex, Ch3 to the olfactory bulb and Ch4 to the neocortex
and amygdala.
With over 90% of its magnocellular neurons being
cholinergic, the nbM is the largest and most well-
studied cell group within the cholinergic basal fore-
brain. Degeneration of the nbM has been correlated
with the presence of dementia in neurological condi-
tions and we have previously hypothesized that subre-
gions of the nbM are differentially affected in
Parkinson’s disease (PD) and AD [9]. By contrast,
pathology within the nvlDBB, which is the second lar-
gest cholinergic group in the basal forebrain and with
up to 70% of neurons being ChAT-positive, is much
less well characterized in neurodegenerative conditions.
Given that hippocampal pathology is implicated in
many dementing disorders and with the hippocampus
receiving extensive innervation from the nvlDBB, it is
important now to revisit this relatively neglected
cholinergic cell group. Furthermore, there is a signifi-
cant overlap between the nvlDBB and adjacent cholin-
ergic loci, so there is as yet no clear consensus on its
anatomical boundaries. Here, on the basis of a review
of the history and anatomy of the rostral basal fore-
brain, we provide recommendations for the visualiza-
tion and sampling of the human nvlDBB. In addition,
we have reviewed clinicopathological studies involving
the nvlDBB and postulate a role for cholinergic inputs
from this nucleus in the cognitive decline seen in PD
and AD.
Historical perspectives
Coining the term diagonal band (of Broca)
In a series of monographs published in the 1870s and
1880s comparing the great limbic lobes (Le grand lobe
limbique) in the brains of different mammalian species
[10–12], French physician and anatomist Pierre Paul
Broca defined a ‘diagonal band’ (La bandelette diagonale)
within a quadrilateral space located directly superior to
the optic chiasm (Figure 1). He described the band as
seen from the inferior surface of the brain to run diago-
nally from the anterior and ‘outermost’ portion of the
‘hippocampal lobe’ to the root of the olfactory tract,
joining the medial olfactory striae at the midline. On
macrodissection, Broca related that the diagonal band
passes in front of the optic chiasm and descends into
the hemisphere. It then travels anterior to the anterior
commissure and the medial septal fibres towards the
genu of the corpus callosum. At a coronal level, this
can be identified clearly as a white-matter bundle med-
ial to the nucleus accumbens of the basal ganglia
Figure 1. An illustration of the diagonal band (d–d0) in the human brain seen from the inferior surface, with the optic tract retracted, as
described in Broca’s monograph in 1888 [12] (left). Coronal section at a level approximately 1.5 cm anterior to the mammillary bodies
(red dashed line) revealed the extent of the diagonal band (black arrows) on both sides of the hemisphere, medial to the basal ganglia
(right). Cd, caudate; IC, internal capsule; LV, lateral ventricle; nAcc, nucleus accumbens; PO, paraolfactory area; Pt, putamen.
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(Figure 1). Further afield, the course of the diagonal
band became difficult to follow, but Broca postulated
that most of the fibres travel behind the corpus callo-
sum and establish a direct connection between this lobe
and the hippocampus. This projection is similar to the
septal arcuate fibres described by Karl Friedrich Bur-
dach in 1822 which is probably identical to the tract
described by Broca [13]. Sir Grafton Elliot Smith, an
Australian-British anatomist, acknowledged Broca’s
work and introduced the term DBB to the English
literature [14].
Defining the ‘nucleus’ of the DBB
Previously mistaken as the medial paraolfactory
nucleus, the nucleus of the DBB (nDBB) was first
described in the brains of box turtles (Cistudo Carolina)
as a cell mass extending from just rostral to the ante-
rior commissure decussation down to the optic chiasm
and caudal to the basolateral surface of the amygdaloid
complex [15]. Subsequently, the nDBB was described in
alligators (Alligator mississippiensis) [16], opossums
(Didelphis virginiana) [17,18], rabbits [17] and rats [19].
The nDBB was also described in the brain of an 8-
month-old human foetus in a comparative neu-
roanatomy study [17]. Johnson reported that the nDBB
started at the lower border of the septum pellucidum
bounded laterally by the olfactory tubercle. He then
described magnocellular and ‘deeply stained’ cells of
the diagonal band extending ‘laterally close beneath
the internal capsule to the temporal limb of the ante-
rior commissure’. He also noticed a bundle or tract
which runs among the diagonal band cells ventral to
the basal ganglia and parallel to the basal surface of
the brain, descending into the temporal pole with the
anterior commissure at its caudal end. Based on his
description, it is likely that he was describing the nbM
and that the bundle he described was not the diagonal
band but was rather the ansa lenticularis and ansa
peduncularis. This highlights the differential organiza-
tion and localization of basal forebrain cell groups in
different animal species. A large mass of nDBB cells
seen in most other mammalian species is replaced by
an extensive nbM in human and other nonhuman pri-
mates. It was not until the 1930s when comparative
neuroanatomical study was performed on the brains of
rhesus monkeys by Papez and Aronson that the pri-
mate nDBB was more properly defined [20]. The
authors noted the important distinction that the nDBB
is a ‘distinct band of deeply staining cells’ embedded
within and following the course of the DBB.
Subdivisions and the two ‘limbs’ of the DBB
Building on Papez’s study, Herald Brockhaus was first
to extensively characterize the nDBB (die kerngruppe
des diagonalen Bandes) in humans in his comparative
study of the basal forebrain cell groups (Basalkernkom-
plex) in primates [21]. Based on the cell morphology,
location and orientation, Brockhaus subdivided the
nDBB rostrocaudally into the nucleus diagonalis septalis,
angularis and ventralis. Subsequently, in a study of the
septum in the human brain, Andy and Stephan
divided the nDBB into ‘tubercular’ and ‘septal’ parts,
with the septal part located against the medial sep-
tum, and the tubercular part located against the ven-
tral aspect (olfactory tubercle) of the brain [22]. In
both subdivision schemes, the borders between subdi-
visions were arbitrarily defined and lack any func-
tional significance.
Experimental lesioning of the fimbria-fornix in rats,
rabbits and the macaque monkey has demonstrated
retrograde degeneration of the MSN and the nDBB, but
limited to the vertical limb of the nucleus [23]. Subse-
quently, division of the nDBB into vertical and horizon-
tal limbs has become well accepted due to their distinct
delineation and anatomical connections. Their distinct
anatomical efferents were confirmed by retrograde tra-
cer experiments, demonstrating that nvlDBB (along
with MSN) projects to the hippocampal formation and
nhlDBB projects to the olfactory bulb.
Anatomy of the nDBB
Extent of the diagonal band at different coronal
levels
As described previously, the diagonal band emerges at
the base of the brain and travels inward medially and
rostrally to join the medial septal fibres by the genu of
the corpus callosum. It is possible to map the extent of
the diagonal band at several coronal levels rostrocau-
dally using established stereotaxic human brain atlases
[24–26] (Figure 2).
At the rostral-most level (here we term the ‘pre-com-
missural level’ of the anterior basal ganglia due to the
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absence of anterior commissure fibre), the DBB can be
identified dorsal and medial to the nucleus accumbens
and interposed with the midline septum pellucidum
(Figure 2a–c). Moving caudally, at the ‘pre-decussation
level’ (as the anterior commissure emerges laterally,
but still anterior to the commissural decussation), the
DBB descends ventrally but remains a compact white
matter bundle situated within the ventromedial aspect
of the basal forebrain (Figure 2d–f). More posteriorly,
where the anterior limb of the anterior commissure
becomes prominent, the DBB often splits into a much
more diffuse structure, with its fibres often interspersed
with streaks of grey matter (Figure 2g–i). At this level,
the DBB is located lateral to a region known as the
paraolfactory area [24,25] and the overall orientation
of the white-matter fibres become more diagonal. Here,
the density of the ChAT-positive neurons is greatest
and correlates best with the nucleus diagonalis angularis
described by Brockhaus [21]. Finally, at the level of the
anterior commissure decussation, the DBB terminates
medial to the ventral striatum and the neurons are
found to be orientated horizontally, parallel to the base
of the forebrain (Figure 2j–l). The white-matter fibres
become very diffuse and it is probably at this coronal
level that Broca described the diagonal band as seen
from the base of the brain [12].
Sampling strategy for the nvlDBB
Exhaustive stereotaxic analysis of the entire diagonal
band may be difficult due to limited availability of
human brain tissue, particularly in clinical or tissue
Figure 2. Serial sections of human basal forebrain tissues at different coronal levels were stained with cresyl violet and luxol fast blue (CV/
LFB) for the visualization of neurons and fibre tracts (a,d,g,j); H&E for identification of anatomical landmarks (b,e,h,k); and immunostained
for ChAT (Millipore AB144P, 1:100 with antigen-retrieval using pressure cooker pretreatment in pH6.0 citrate buffer) for the identification
of the cholinergic population within the nvlDBB (c,f,i,l). The DBB was identified at four distinct levels, arranged rostrally (top) to caudally
(bottom). (a–c) Precommissural level. At this level, the nucleus accumbens is prominent with the absence of anterior commissure fibre. The
DBB can be seen at the medial and dorsal aspects, merging with the medial septum. Here, the Ch1 and Ch2 populations are often difficult to
be distinguished. (d–f) Rostral predecussation level. The anterior commissure begins to emerge and the DBB is situated slightly more
ventrally. ChAT-positive neurons within the nvlDBB increase in density. (g–i) Caudal predecussation level. At this level, the DBB sits at the
ventromedial aspect of the basal forebrain and the Ch2 population reaches the maximum. (j–l) Anterior commissure decussation level. Here,
the anterior commissure begins to decussate and the DBB is situated ventrally, parallel to the ventral border of the basal forebrain. ChAT-
positive neurons of the nvlDBB intermingle with those in the nbM at this level. Asterisk (*) denotes area of maximum density of ChAT-
positive neurons. BnST, bed nucleus of stria terminalis; Cd, caudate; ChAT, choline acetyltransferase; Ch1, cholinergic neurons in the medial
septal nucleus; Ch2, cholinergic neurons in the vertical limb of the diagonal band of Broca; Ch4, cholinergic neurons in the nbM; nvlDBB,
nucleus of the vertical limb of the DBB; EC, external capsule; GP, globus pallidus; IC, internal capsule; InCx, insular cortex; nAcc, nucleus
accumbens; Pt, putamen; VS, ventral striatum; nbM, Nucleus basalis of Meynert.
Figure 3. Photograph showing two sliced brain slabs approximately 1.0 cm (right) and 1.5 cm (left) anterior to the coronal level of the
mammillary bodies. Recommended sampling for the nvlDBB is outlined by a red box at the level at or just rostral to the anterior commissure
decussation. nvlDBB, nucleus of the vertical limb of the diagonal band of Broca.
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bank setting. Furthermore, the heterogeneity of cell
density and anatomy do not lend themselves to sam-
pling the entire extent. Instead, we propose that sam-
pling a dense and reliably defined part of the nvlDBB
would provide a more representative and accurate rep-
resentation and enable consistent sampling of this
important region. Depending on brain size, the area of
maximal nvlDBB density is situated approximately 10–
15 mm anterior to the coronal level of the mid-mam-
millary body (Figure 3).
Due to the lack of clearly defined boundaries between
overlapping cell groups within the basal forebrain
cholinergic complex, the following guide can be used to
distinguish the nvlDBB from surrounding basal fore-
brain nuclei (Table 1):
First, isolated nvlDBB neurons are often found at the
‘pre-decussation’ level (Figure 2). At the rostral-most
level (typically precommissural as shown in Figure 2a),
the MSN forms a continuous, vertically orientated col-
umn of magnocellular neurons with the nvlDBB
embedded within the septal grey matter. However, in
contrast to the nvlDBB, only approximately 10% of
MSN neurons are ChAT-immunopositive. At this coro-
nal level, previous authors have separated MSN from
nvlDBB based on a rarefaction of ChAT-immunostained
neuron density [6] and different neuronal morphology
(with MSN neurons being generally smaller and ovoid
in shape) [7]. At the level of the anterior commissure
decussation, the caudoventral part of the nvlDBB is
often found to be interdigitated with the medial nbM
magnocellular neurons, particularly the anteromedial
sector of the Ch4 (Ch4am) [8].
Second, the direction of general dendritic orientation
of the neurons is important for distinguishing nvlDBB
from other neuronal groups. In a detailed morphomet-
ric study using thick (240 lm) basal forebrain sections
with a Golgi impregnation technique, Arendt and col-
leagues [27] described a gradual shift in dendritic ori-
entation from a ventrodorsal orientation at the MSN
and the rostral nvlDBB to a mediolateral orientation at
the caudal nvlDBB and nbM. Neurons in the nvlDBB
should be orientated at an oblique angle from the ven-
tral border of the basal forebrain, which can be distin-
guished from those in the nbM which are orientated in
a parallel fashion.
As suggested by various investigators, neurons in the
nvlDBB are interspersed within the DBB [21,25,28],
and counterstaining serial sections stained for myelin
(luxol-fast blue staining) can be helpful for identifying
where the neurons reside with respect to the DBB fibre
tracts.
A probabilistic approach to identify neurons within
the nvlDBB
Due to the overlapping arrangement of basal forebrain
structures, intersubject variability may greatly affect
delineation of nvlDBB from surrounding cholinergic cell
groups. One approach to minimize uncertainty is to use
a stereotaxic probabilistic map of brain structures, an
approach popular among brain imaging scientists. This
technique uses a small sample of serially and histologi-
cally stained, post-mortem brain samples mapped on to
a reference brain with magnetic resonance imaging
(MRI) images, creating a probabilistic map, showing
the likelihood for a certain structure found to be within
a reference space in brain imaging [29]. Probabilistic
maps of various cortical and subcortical regions,
including the basal forebrain, are presently available
[29]. Zaborszky and colleagues [30] have published
detailed stereotaxic probabilistic maps of the four basal
forebrain cholinergic cell groups also including the
often neglected posterior nbM (Ch4p) component in the
mapping. However, in their study, no distinction was
made between nvlDBB (Ch2) and MSN (Ch1). Further-
more, their initial delineation of the four cholinergic
cell groups was largely based on Mesulam and col-
leagues’ classification on rhesus monkeys [7], which
may not reliably map well on to human brains. For
future brain imaging studies focusing on the nvlDBB, a
Table 1. Guidelines for the identification of neurons within the
nucleus of the vertical limb of the diagonal band of Broca
Feature Description
Anteroposterior
level at coronal plane
Neurons can be identified at the
‘pre-decussation’ level (Figure 2d,g)
of the anterior basal ganglia
Dendritic orientation Neurons are orientated at an oblique
angle to the ventral border of the
basal forebrain. Nucleus basalis of
Meynert neurons are orientated
parallel to the ventral border
Visibility of
diagonal band
Cells are embedded within the
myelinated fibres of the diagonal
band, identified on myelin
counterstain or myelin-stained
serial sections
© 2018 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society
NAN 2018; 44: 647–662
652 A. K. L. Liu et al.
more detailed probabilistic map separating the nvlDBB
and the MSN may be required.
Distinction between the anterior (rostral) and
posterior (caudal) basal forebrain compartments
Although different basal forebrain compartments
appear to be continuous, there have been suggestions
that they are developed from a dual embryological ori-
gin. Based on observations in rats and cats, the caudal
basal forebrain (including the nbM) arises earlier than
the rostral components (MSN and nvlDBB) which later
merge and form a continuum (reviewed in [2]).
Although it is unknown whether the same is true for
humans, one could speculate that component-specific
vulnerability may exist in different neurological disor-
ders. In one recent MRI study on patients with amnes-
tic mild cognitive impairment and controls, Cantero
and colleagues reported the volume changes in the ros-
tral basal forebrain including the MSN and nvlDBB sig-
nificantly correlated with changes in hippocampal
volume in both groups, whereas that of the caudal
basal forebrain only significantly correlated with varia-
tions of amygdala and temporal cortical volumes.
Hence, in future studies, it is important to carefully
delineate these basal forebrain nuclei and perform more
in-depth analysis.
What about the nucleus of the horizontal limb of
the diagonal band?
Cells in the nhlDBB can be found both amongst the
fibres of the horizontal portion of the DBB and beneath
the substantia innominata, parallel to the ventral sur-
face of the basal forebrain. They are described as gener-
ally smaller than nbM neurons (10–15 lm in
diameter) and are fusiform and multipolar in shape
[7,31]. However, in primates, only approximately 1%
of the nhlDBB neurons are cholinergic, overlapping
heavily with neurons in the nbM [7] and understand-
ably for studies of cholinergic innervation, this nucleus
is often neglected.
Revisiting the cholinergic nvlDBB in
different neurological diseases
After establishing the anatomy of the nvlDBB, we car-
ried out an extensive literature review to establish the
pattern of cell loss within the nvlDBB in several neuro-
logical disorders. Due to the difficulty in delineating
boundaries, some studies grouped the MSN and nvlDBB
as they share a common efferent pathway towards the
hippocampal complex [4,32–36]. Furthermore, most
investigators have used the terminology Ch2 when
quantifying neuronal loss within nvlDBB, though this
term should strictly be used on ChAT-immunostained
tissue to define the local cholinergic population. Thus,
in this review, we avoid using Ch terminology unless
the particular study carried out quantitative assessment
with a specific cholinergic marker.
The nvlDBB in AD
Quantitative studies on the nvlDBB in AD have
reported conflicting results ranging from no cell loss to
a maximum of 84% loss (Table 2). Loss of nvlDBB neu-
rons was mainly reported in earlier studies using cresyl
violet (Nissl stain) for the visualization of neurons, and
the degree of cell loss did not appear to differ between
early and late-onset AD [37]. Neuronal loss in the
nvlDBB was correlated to senile plaque density in the
hippocampus of AD cases by one group [4], but this
correlation was not observed in another study [37]. It
was later suggested that neurons within the basal fore-
brain cholinergic group undergo atrophy instead of cell
loss in AD [34]. Indeed, when size criteria were elimi-
nated for the quantification of neurons within the
nvlDBB, no significant cell loss was observed in AD
cases relative to age-matched controls. This is sup-
ported by the higher reported nvlDBB cell loss in stud-
ies only quantifying neurons larger than 30 lm in
diameter (70–80% loss) [37,38] compared with those
quantifying neurons larger than 20 lm in diameter
(41–67.5% loss) [4,32,39,40]. Using appropriate
immunohistochemistry, a size criterion to distinguish
neurons from other cell types is not needed as both
large and atrophied neurons will be stained, although
the latter will only be positive if metabolically active
and preserving a cholinergic phenotype. One study
using immunohistochemistry to label nerve growth fac-
tor (NGF) receptors (NGFR), which coexpress in over
95% of the basal forebrain cholinergic neurons, failed
to observe any significant neuronal loss in the nvlDBB
in the seven AD cases studied [33]. This is supported
by a previous finding that NGF gene expression is
decreased in the nbM but not the MSN and nvlDBB of
© 2018 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society
NAN 2018; 44: 647–662
Nucleus of the diagonal band of Broca 653
T
a
b
le
2
.
S
tu
d
ie
s
q
u
a
n
ti
fy
in
g
ch
a
n
g
es
o
f
th
e
n
v
lD
B
B
a
n
d
M
S
N
n
eu
ro
n
s
Y
ea
r
A
u
th
or
s
S
ta
in
s
fo
r
id
en
ti
fi
ca
ti
on
of
n
eu
ro
n
s
N
eu
ro
n
al
co
u
n
t
cr
it
er
ia
D
is
ea
se
n
M
ea
n
ag
e
at
de
at
h
%
n
vl
D
B
B
lo
ss
fr
om
co
n
tr
ol
%
M
S
N
lo
ss
fr
om
co
n
tr
ol
%
n
vl
D
B
B
+
M
S
N
lo
ss
fr
om
co
n
tr
ol
A
D 1
9
8
3
A
re
n
d
t
et
al
.
[3
9
]
N
is
sl
>
2
0
lm
d
ia
m
et
er
,
a
b
u
n
d
a
n
t
N
is
sl
su
b
st
a
n
ce
A
D
1
4
6
0
.8
6
7
.5
0
%
6
3
.7
1
%
–
1
9
8
5
A
re
n
d
t
et
al
.
[4
]
N
is
sl
>
2
0
lm
d
ia
m
et
er
,
a
b
u
n
d
a
n
t
N
is
sl
su
b
st
a
n
ce
A
D
5
6
0
.8
–
–
6
2
.5
0
%
1
9
8
6
E
ti
en
n
e
et
al
.
[3
7
]
N
is
sl
>
3
0
lm
d
ia
m
et
er
,
v
is
ib
le
n
u
cl
eu
s,
a
b
u
n
d
a
n
t
N
is
sl
su
b
st
a
n
ce
A
D
9
7
8
.9
7
0
%
(m
ea
n
);
8
3
.5
6
%
(m
a
x
)
–
–
1
9
8
7
G
er
tz
et
al
.
[3
2
]
N
is
sl
>
2
0
lm
d
ia
m
et
er
,
n
u
cl
ea
te
d
n
er
v
e
ce
ll
s
A
D
7
9
1
.1
–
–
5
4
.2
0
%
1
9
8
8
W
il
co
ck
et
al
.
[4
0
]
N
is
sl
>
2
0
lm
d
ia
m
et
er
,
v
is
ib
le
n
u
cl
eo
lu
s,
a
b
u
n
d
a
n
t
N
is
sl
su
b
st
a
n
ce
A
D
1
0
7
9
.3
4
1
.0
9
%
(m
ea
n
);
4
1
.4
2
%
(m
a
x
)
–
–
1
9
8
9
M
u
fs
o
n
et
al
.
[3
3
]
N
G
F
R
Im
m
u
n
o
re
a
ct
iv
e
ce
ll
so
m
a
A
D
7
7
7
–
–
1
6
.7
%
(n
.s
.)
1
9
9
0
V
o
g
el
s
et
al
.
[3
4
]
N
is
sl
N
is
sl
-s
ta
in
ed
,
v
is
ib
le
n
u
cl
eo
lu
s
A
D
1
0
8
4
.5
–
–
N
o
lo
ss
1
9
9
3
L
eh
er
ic
y
et
al
.
[6
]
C
h
A
T
C
h
A
T
-p
o
si
ti
v
e
ce
ll
b
o
d
y
(d
is
p
la
y
in
g
ei
th
er
st
ro
n
g
o
r
li
g
h
t
im
m
u
n
o
st
a
in
in
g
)
A
D
4
8
9
.5
5
6
%
5
3
%
5
5
%
1
9
9
5
A
re
n
d
t
et
al
.
[4
3
]
N
is
sl
>
2
0
lm
d
ia
m
et
er
,
v
is
ib
le
n
u
cl
eu
s,
a
b
u
n
d
a
n
t
N
is
sl
su
b
st
a
n
ce
A
D
1
5
6
5
–
–
A
p
p
ro
x
im
a
te
ly
7
8
%
†
(v
s.
a
d
u
lt
co
n
tr
o
l)
;
a
p
p
ro
x
im
a
te
ly
6
4
.5
%
(v
s.
el
d
er
ly
co
n
tr
o
l)
1
9
9
5
P
o
ir
ie
r
et
al
.
[3
8
]
N
is
sl
&
A
C
h
E
A
C
h
E
-p
o
si
ti
v
e,
>
3
0
l
m
,
a
b
u
n
d
a
n
t
N
is
sl
su
b
st
a
n
ce
o
n
a
d
ja
ce
n
t
se
ct
io
n
A
D
8
(f
ro
m
2
4
)
U
n
k
n
o
w
n
fo
r
th
e
ei
g
h
t
se
le
ct
ed
ca
se
s
A
p
p
ro
x
im
a
te
ly
6
0
%
†
(A
p
o
E
4
n
eg
a
ti
v
e)
;
a
p
p
ro
x
im
a
te
ly
8
0
%
†
(A
p
o
E
4
p
o
si
ti
v
e)
–
–
2
0
0
6
F
u
ji
sh
ir
o
et
al
.
[3
5
]
C
h
A
T
C
h
A
T
-i
m
m
u
n
o
p
o
si
ti
v
e
ce
ll
s
A
D
4
8
3
.5
–
–
n
.s
.
L
ew
y
b
o
d
y
d
is
o
rd
er
s
1
9
8
3
W
h
it
eh
o
u
se
et
al
.
[4
2
]
N
is
sl
>
3
0
lm
d
ia
m
et
er
,
a
b
u
n
d
a
n
t
N
is
sl
su
b
st
a
n
ce
P
D
3
6
0
n
.s
.
–
–
P
D
D
2
7
1
.5
4
4
.8
0
%
–
–
1
9
8
3
A
re
n
d
t
et
al
.
[3
9
]
N
is
sl
>
2
0
lm
d
ia
m
et
er
,
a
b
u
n
d
a
n
t
N
is
sl
su
b
st
a
n
ce
P
D
5
5
8
.5
7
6
.6
0
%
6
9
.8
0
%
–
© 2018 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society
NAN 2018; 44: 647–662
654 A. K. L. Liu et al.
T
a
b
le
2
.
(C
on
ti
n
u
ed
)
Y
ea
r
A
u
th
or
s
S
ta
in
s
fo
r
id
en
ti
fi
ca
ti
on
of
n
eu
ro
n
s
N
eu
ro
n
al
co
u
n
t
cr
it
er
ia
D
is
ea
se
n
M
ea
n
ag
e
at
de
at
h
%
n
vl
D
B
B
lo
ss
fr
om
co
n
tr
ol
%
M
S
N
lo
ss
fr
om
co
n
tr
ol
%
n
vl
D
B
B
+
M
S
N
lo
ss
fr
om
co
n
tr
ol
1
9
9
5
A
re
n
d
t
et
al
.
[4
3
]
N
is
sl
>
2
0
lm
d
ia
m
et
er
,
v
is
ib
le
n
u
cl
eu
s,
a
b
u
n
d
a
n
t
N
is
sl
su
b
st
a
n
ce
P
D
6
5
8
.2
–
–
A
p
p
ro
x
im
a
te
ly
7
5
%
†
(v
s.
a
d
u
lt
co
n
tr
o
l)
;
a
p
p
ro
x
im
a
te
ly
5
9
.7
%
(v
s.
el
d
er
ly
co
n
tr
o
l)
2
0
0
6
F
u
ji
sh
ir
o
et
al
.
[3
5
]
C
h
A
T
C
h
A
T
-i
m
m
u
n
o
p
o
si
ti
v
e
ce
ll
s
D
L
B
8
7
5
–
–
A
p
p
ro
x
im
a
te
ly
4
5
%
†
2
0
1
4
H
a
ll
et
al
.
[3
6
]
C
h
A
T
C
h
A
T
-i
m
m
u
n
o
p
o
si
ti
v
e
ce
ll
s
P
D
5
6
0
.4
–
–
n
.s
.
P
D
D
6
6
0
.2
–
–
n
.s
.
O
th
er
n
eu
ro
lo
g
ic
a
l
d
is
ea
se
s
1
9
8
3
W
h
it
eh
o
u
se
et
al
.
[4
2
]
N
is
sl
>
3
0
lm
d
ia
m
et
er
,
a
b
u
n
d
a
n
t
N
is
sl
su
b
st
a
n
ce
P
o
st
-e
n
ce
p
h
a
li
ti
c
P
a
rk
in
so
n
is
m
1
5
0
.3
8
5
.1
6
%
in
cr
ea
se
–
–
1
9
8
3
A
re
n
d
t
et
al
.
[3
9
]
N
is
sl
>
2
0
lm
d
ia
m
et
er
,
a
b
u
n
d
a
n
t
N
is
sl
su
b
st
a
n
ce
K
o
rs
a
k
o
ff
’s
d
is
ea
se
3
4
3
.3
5
6
.6
7
%
4
0
.3
3
%
–
1
9
8
4
A
re
n
d
t
et
al
.
[4
7
]
N
is
sl
>
2
0
lm
d
ia
m
et
er
,
a
b
u
n
d
a
n
t
N
is
sl
su
b
st
a
n
ce
C
JD
1
4
7
–
–
4
3
%
(r
ig
h
t
h
em
is
p
h
er
e)
;
3
9
%
(l
ef
t
h
em
is
p
h
er
e)
1
9
8
5
B
a
u
m
a
n
et
al
.
[4
8
]
N
is
sl
V
is
ib
le
n
u
cl
eo
li
In
fa
n
ti
le
a
u
ti
sm
1
2
9
1
1
%
(n
.s
.)
5
4
%
in
cr
ea
se
–
1
9
9
5
A
re
n
d
t
et
al
.
[4
3
]
N
is
sl
>
2
0
lm
d
ia
m
et
er
,
v
is
ib
le
n
u
cl
eu
s,
a
b
u
n
d
a
n
t
N
is
sl
su
b
st
a
n
ce
A
g
ei
n
g
1
1
7
8
.1
–
–
A
p
p
ro
x
im
a
te
ly
3
8
%
†
(v
s.
a
d
u
lt
co
n
tr
o
l)
K
o
rs
a
k
o
ff
’s
d
is
ea
se
w
it
h
W
er
n
ic
k
e’
s
en
ce
p
h
a
lo
p
a
th
y
6
3
9
.5
–
–
A
p
p
ro
x
im
a
te
ly
6
8
%
†
(v
s.
a
d
u
lt
co
n
tr
o
l)
;
a
p
p
ro
x
im
a
te
ly
4
8
.4
%
(v
s.
el
d
er
ly
co
n
tr
o
l)
2
0
1
3
R
€ u
b
et
al
.
[5
0
]
N
is
sl
A
ll
co
u
n
ta
b
le
N
is
sl
-s
ta
in
ed
n
eu
ro
n
s
S
C
A
2
4
5
4
.8
7
4
%
7
2
%
–
S
tu
d
ie
s
u
si
n
g
im
m
u
n
o
h
is
to
ch
em
ic
a
l
m
a
rk
er
s
fo
r
th
e
id
en
ti
fi
ca
ti
o
n
o
f
ch
o
li
n
er
g
ic
n
eu
ro
n
s
w
it
h
in
th
e
n
v
lD
B
B
a
re
sh
a
d
ed
in
g
re
y
.
A
C
h
E
,
a
ce
ty
lc
h
o
li
n
es
te
ra
se
;
A
D
,
A
lz
h
ei
m
er
’s
d
is
ea
se
;
C
h
A
T
,
ch
o
li
n
e
a
ce
ty
lt
ra
n
sf
er
a
se
;
C
JD
,
C
re
u
tz
fe
ld
t–
Ja
k
o
b
d
is
ea
se
;
D
L
B
,
d
em
en
ti
a
w
it
h
L
ew
y
b
o
d
ie
s;
M
S
N
,
m
ed
ia
l
se
p
ta
l
n
u
cl
eu
s;
N
G
F
R
,
n
er
v
e
g
ro
w
th
fa
ct
o
r
re
ce
p
to
r;
n
.s
.,
n
o
si
g
n
ifi
ca
n
ce
;
n
v
lD
B
B
,
n
u
cl
eu
s
o
f
th
e
v
er
ti
ca
l
li
m
b
o
f
d
ia
g
o
n
a
l
b
a
n
d
o
f
B
ro
ca
;
P
D
,
P
a
rk
in
so
n
’s
d
is
ea
se
;
P
D
D
,
P
D
d
em
en
ti
a
;
S
C
A
2
,
sp
in
o
ce
re
b
el
la
r
a
ta
x
ia
ty
p
e
2
.
†
A
p
p
ro
x
im
a
ti
o
n
fr
o
m
g
ra
p
h
s
w
it
h
in
th
e
st
u
d
y
.
© 2018 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society
NAN 2018; 44: 647–662
Nucleus of the diagonal band of Broca 655
AD cases [41]. However, studies using ChAT immuno-
histochemistry on nvlDBB neurons reported contrasting
results. An early study on four AD cases (mean age at
death = 89.5) found 56% ChAT-positive neuronal loss
in the nvlDBB and 53% loss in the MSN with no signif-
icant change in mean neuronal cross-sectional area
[6], whereas a more contemporary study found neu-
ronal shrinkage but no significant loss of Ch1/2 neu-
rons in four AD cases (mean age at death = 83.5)
[35]. One explanation for these differences could be a
differing sensitivity of anti-ChAT antibodies and
immunohistochemical amplification techniques. In
Lehericy et al.’s study, primary antibodies were incu-
bated for 3 days prior to signal amplification with per-
oxidase antiperoxidase technique, possibly suggesting a
lower sensitivity of the primary antibody used. There-
fore, it is likely that neurons with a diminished expres-
sion of ChAT, particularly in AD [34], may not be
stained and quantified. Nevertheless, there is a general
consensus that this rostral cholinergic basal forebrain
is relatively spared in AD.
The nvlDBB in PD and Lewy body dementias
In contrast to AD, there have only been a small num-
ber of studies investigating neuronal loss in the nvlDBB
in Lewy body disorders (Table 2). Whitehouse and col-
leagues used Nissl staining for neuronal counts and
first reported 44.8% loss of nvlDBB neurons in two PD
with dementia (PDD) cases but no significant change in
three PD cases [42]. Subsequently, using a neuronal
counting criterion to include neurons larger than
20 lm in diameter, one study with five PD cases
reported 76.6% loss of nvlDBB and 69.8% MSN neu-
rons [4] and another with six PD cases reported 59.7%
loss of nvlDBB and MSN neurons [43]. Recently, with
ChAT-immunohistochemistry, one study with eight
dementia with Lewy bodies (DLB) cases reported signifi-
cant Ch1/2 loss relative to age-matched controls and
AD cases [35]. The cell loss was accompanied by a
reduction of mean surface area of ChAT-positive cell
bodies, an indicator of cell size. Another study using
post-mortem tissues from a prospective and clinically
well-characterized cohort found an increased variation
in cell number but no significant ChAT-positive neu-
ronal loss in the Ch1/2 region of five PD and six PDD
cases, although a trend towards a decrease in neuron
number was seen in progression from PD to PDD [36].
Both studies have linked the change in nvlDBB neu-
ronal count in Lewy body disease cases to an increase
in ubiquitin-positive, alpha-synuclein Lewy neurite
pathology in the CA2 subsector of the hippocampus, as
reported by previous studies [44–46], which has been
associated with cognitive impairment seen in Lewy
body disorders.
The nvlDBB in other neurological conditions
Degeneration of the nvlDBB is not exclusive to neu-
rodegenerative diseases (Table 2). Indeed, an approxi-
mately 38% nvlDBB and MSN neuronal loss has been
reported in aged brains (mean age at death = 78.1)
when compared to younger adult controls [43]. In Kor-
sakoff’s disease, neuronal loss within the nvlDBB has
been reported to be about 50% [39,43]. Single case
studies on post-encephalitic Parkinsonism [42], Creutz-
feldt-Jakob disease [47] and infantile autism [48] have
all reported varying degrees of alteration in neuronal
count/density within the nvlDBB. Interestingly, severe
basal forebrain cholinergic degeneration has been
reported in spinocerebellar ataxia (SCA) types 1 (SCA1)
and 2 (SCA2) with relatively well-preserved cognitive
function [49,50]. In particular, one study reported neu-
ronal loss in the MSN (72% loss), nvlDBB (74% loss)
and nbM (86% loss) in four SCA2 cases compared with
controls without significant correlation with tau
pathology according to Braak and Braak AD stage
[50], indicating a possible causal role of polyglutamine
expansion in the death of basal forebrain cholinergic
neurons.
Consideration of the noncholinergic
components in the cholinergic basal
forebrain complex
As discussed previously, 90% of nbM magnocellular
neurons in the primate basal forebrain express the
cholinergic marker, ChAT [7]. However, the proportion
of cholinergic to noncholinergic neurons is much smal-
ler in rostral cholinergic groups (10% in MSN, 70% in
nvlDBB and 1% in nhlDBB). Therefore, previous studies
using Nissl staining for quantification of neurons in the
MSN and nvlDBB will also be describing pathology in
the noncholinergic components of the basal forebrain.
The neurochemical profiles of noncholinergic rostral
basal forebrain neurons have been extensively
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investigated in rodents and nonhuman primates. Tyro-
sine-hydroxylase-positive neurons have been found in
the basal forebrain [51], while c-aminobutyric acid
(GABA)-ergic [52] and glutamatergic neurons [53]
form the largest noncholinergic hippocampal-projecting
group within MSN/nvlDBB. In rodent studies, low fre-
quency theta rhythm in the hippocampus is generated
in the MSN-nvlDBB, mainly through GABAergic output
neurons, and contributes to spatial learning and mem-
ory [54,55]. GABAergic output neurons from the MSN/
nvlDBB form synaptic contacts with hippocampal
interneurons and act as pacemaker cells for theta
rhythm with disinhibition of hippocampal pyramidal
neurons [55]. Recent studies also showed glutamater-
gic neurons modulate theta rhythm via local modula-
tion of GABAergic neurons within MSN/nvlDBB [56].
Since MSN/nvlDBB neuronal loss was initially reported
in AD cases with little or no significant loss in the
ChAT-immunopositive component, it could be hypothe-
sized that there may be a greater GABAergic and gluta-
matergic MSN/nvlDBB neuronal loss in AD.
NGF and its receptors (high affinity, trkA and low
affinity, p75NTR) colocalize within the human choliner-
gic basal forebrain [33,57,58] and reduced NGFR levels
and mRNA expression were reported in the nbM, but
not the nvlDBB, of AD brains [33,41]. In addition,
galanin, a 19 or 30-amino acid long peptide in human
brain, is coexpressed by basal forebrain cholinergic
neurons. In AD and PD, galanin was shown to display
a higher degree of presence (‘hyperinnervation’) in sur-
viving ChAT-positive neurons, particularly in the ante-
rior basal forebrain [59–61].
Functional correlates to the differential
pattern of nvlDBB cell loss in Alzheimer’s
and PD
Functional connections of the nvlDBB in the human
brain remain largely unknown, but case studies from
specific vascular lesions have provided some clues.
There are two major sources of vascular supply to the
basal forebrain. The anterior/septal sector of the basal
forebrain (including MSN and nvlDBB) is supplied by
perforator arteries of the anterior communicating
artery; the caudal/horizontal sector (including the
nhlDBB and nbM) is supplied by the anterior lenticulos-
triate branches from the proximal (A1) sector of the
anterior cerebral artery [62].
Amnesia and Korsakoff’s syndrome-like symptoms
have been reported in patients after repairs of ruptured
anterior communicating artery aneurysm causing
infarction of the anterior basal forebrain [63–71].
These lesions tend to be widespread and affect multiple
basal forebrain nuclei and fibre tracts. Nevertheless,
two studies reported cases with relatively discrete basal
forebrain lesions [72,73]. In one of the cases reported
by Damasio and colleagues, surgical clipping of an
aneurysm at the A1 and A2 junction of the left ante-
rior cerebral artery was performed [72]. The anatomi-
cal regions affected by this lesion were similar to a case
reported by Abe and colleagues showing an isolated
lesion at the right nvlDBB, anterior hypothalamus and
lamina terminalis [73]. Hypoperfusion caused by the
lesion extended to both sides of the hemisphere as
shown by single-photon emission computed tomogra-
phy scan using 99mTc-d, l-hexamethyl propyleneamine
oxime. In both cases, neuropsychiatric tests were per-
formed and the patients exhibited anterograde and ret-
rograde amnesia. However, there was a benefit with
cueing that indicated a deficit in retrieval rather than
encoding of memory. A similar amnestic profile was
reported by Morris and colleagues on a case with surgi-
cal resection of a low-grade astrocytoma at the right
anterior basal ganglia region containing the nvlDBB
[74]. From these three cases, it is evident that the
nvlDBB is involved in memory function and in particu-
lar memory retrieval.
According to the Movement Disorder Society Task
Force consensus criteria on the diagnosis of PDD,
patients with PDD may suffer impairment in free recall
which improves with cueing [75]. There is a general
agreement that memory impairment in PD involves def-
icit in memory retrieval rather than storage/encoding
memory as in AD [75]. Therefore, it can be deduced
that nvlDBB may be more significantly affected in Lewy
body disorders than in AD. This is supported by an
aforementioned post-mortem study by Fujishiro and
colleagues reporting a significant decrease in ChAT-
positive neurons in the nvlDBB of DLB cases relative to
AD and age-matched controls [35]. However, a recent
imaging study with 11 AD and 11 DLB patients failed
to demonstrate difference in MSN/nvlDBB atrophy on
structural MRI scans [76]. Instead, only a trend reduc-
tion in MSN/nvlDBB volume was observed in AD
(17.5%) and DLB (17.4%). This discrepancy may be
due to the fact that in vivo MRI-based measurement
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cannot distinguish whether neuronal loss or cell atro-
phy contributes to the volumetric changes. Thus, fur-
ther post-mortem studies will be required.
Ch2 and CA2: a possible connection?
Similar to the nvlDBB, the hippocampal CA2 subfield is
a relatively unexplored region in the human brain.
Recently, using retrograde and adeno-associated virus-
expressing anterograde tracers, reciprocal connections
between the MSN-nvlDBB and the CA2 have been iden-
tified in the mouse brain [77]. Ubiquitin- and alpha-
synuclein-immunopositive neuritic pathology in Lewy
body disorders has been found confined to the CA2
subfield in the hippocampus [36,44–46], in contrast to
the preferential deposition of neurofibrillary tangles in
the CA1 region in AD [78]. Coincidentally, this is the
subregion where the highest density of ChAT-positive
fibres and punctate immunoprecipitates can be identi-
fied in the human hippocampus [79]. Although the
presence of hippocampal dopaminergic innervation has
been extensively reported in rodents [80], evidence of
such projection in the human brain was lacking with
one study failing to demonstrate the presence of
monoaminergic fibre in the hippocampus of DLB and
aged control brains using immunostaining with antity-
rosine hydroxylase antibodies [45]. Significant hip-
pocampal cholinergic depletion was found in PDD cases
when compared with PD and control [36]. The sub-
field-specific protein aggregation pathology and cholin-
ergic deficits in the hippocampus of Lewy body
disorders appeared to be associated with the severe
nvlDBB cholinergic depletion described in the sections
above. As a result, it can be hypothesized that Lewy
pathologies in the CA2 subregion of the hippocampus
can cause neurodegeneration of the cholinergic compo-
nent of the nvlDBB (Ch2) leading to deficits in retrieval
memory, while a predominant noncholinergic neuronal
loss of the nvlDBB may contribute to the encoding and
storage memory deficits in AD (Figure 4).
Conclusion
The functional importance of the diagonal band in
human cognition has long been recognized owing to its
anatomical position in the limbic loop. However, the
pathological significance of the nucleus of the diagonal
band, particularly the nvlDBB, in neurodegenerative
conditions has not been studied in detail. There has
been a lack of consensus quantifying cholinergic cell
loss in AD and Lewy body disorders primarily due to
the following: (i) the absence of clear anatomical
boundaries to delineate nvlDBB from surrounding mag-
nocellular basal forebrain nuclei; (ii) application of size
criteria for neuronal quantification discounting the pos-
sibility of cell shrinkage; and (iii) most studies
Figure 4. Proposed schema for the neurodegenerative changes within cholinergic and noncholinergic populations of the nvlDBB in Lewy
body disorders and AD with possible clinicopathological correlates. AD, Alzheimer’s disease; CA, Cornu Ammonis; Ch2, cholinergic
population of the vertical limb of the diagonal band of Broca; DG, dentate gyrus; GABA, c-aminobutyric acid; LBD, Lewy body disorder;
nvlDBB, nucleus of the vertical limb of the DBB.
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attributing magnocellular neuronal loss in the nvlDBB
to cholinergic nerve cells without use of a cholinergic
immunohistochemical marker. Thus, by reviewing the
history of DBB anatomy, we have established recom-
mended sampling criteria for identifying the nvlDBB
suitable for future clinicopathological studies. In addi-
tion, we recommend the use of specific cholinergic
immunohistochemical markers such as ChAT for the
identification and quantification of Ch2 (cholinergic
component of nvlDBB) neurons. Further studies investi-
gating the changes in the noncholinergic components
of the nvlDBB, such as GABAergic neurons and gluta-
matergic interneurons, will also be needed.
Through the study of cases with discrete vascular or
other lesions affecting the rostral basal forebrain, it can
be deduced that the nvlDBB plays a discrete role in retrie-
val memory function, severely affected in Lewy body dis-
orders. Extrapolating from existing clinicopathological
studies, we propose an anatomical and functional
connection between Ch2 and the CA2 subfield in the
hippocampus which may be especially vulnerable to
Lewy pathologies. Further clinicopathological investiga-
tions are now needed to test this hypothesis. With the
development of novel tissue clearing techniques which
have successfully been applied to post-mortem human
brain tissues for the visualization of anatomical struc-
tures and their connections in three dimensions [81–83],
the detailed projection of cholinergic fibres from the
nvlDBB in the human brain may be mapped out,
shedding more light on the detailed role of the cholinergic
nvlDBB in cognitive function.
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